Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

被引：3
|
作者：
Ardizzoni, Andrea
Razis, Evangelia
Lichinitser, Mikhail
Yilmaz, Ugur
Grigorescu, Alexandru C.
Morero, Jose Luis
Skrickova, Jana
Cervantes, Guadalupe
Gottfried, Maya
Van Meerbeeck, Jan
机构：
[1] Univ Parma, Parma, Italy
[2] Hygeia Hosp, Athens, Greece
[3] NN Blochin Russian Oncol Res Ctr, Moscow, Russia
[4] Dokuz Eylu Univ, Med Fac, Izmir, Turkey
[5] Bucharest Oncol Inst, Bucharest, Romania
[6] Hosp Maria Ferrer, Buenos Aires, DF, Argentina
[7] Univ Hosp Brno, Brno, Czech Republic
[8] ISSSTE, Hosp Noviembre Ctr Medico, Mexico City, DF, Mexico
[9] Meir Sapir Med Ctr, Kefar Sava, Israel
[10] Univ Hosp, Ghent, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期
关键词：
D O I：
10.1097/01.JTO.0000283158.26734.bc
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S342 / S342
页数：1
相关论文
共 50 条
  • [21] Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (07) : 991 - 997
  • [22] FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY
    Wu, Yi-Long
    Liam, Chong-Kin
    Zhou, Caicun
    Wu, Gang
    Liu, Xiaoqing
    Zhong, Zhaoyang
    Lu, Shun
    Cheng, Ying
    Han, Baohui
    Chen, Lei
    Zhu, Yunzhong
    Qin, Shukui
    Huang, Cheng
    Pan, Hongming
    Liang, Houjie
    Li, Enxiao
    How, Soon Hin
    Jiang, Guoliang
    Cherry, Marie
    Fernando, Lynn
    Chen, Meng
    Zuo, Yunxia
    Ladrera, Guia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S603 - S604
  • [23] Efficacy of erlotinib in patients (pts) with advanced non-small-cell lung cancer (NSCLC) relative to clinical characteristics: Subset analyses from the TRUST study
    Allan, S. G.
    Bosquee, L.
    Franke, A.
    Pirker, R.
    Scagliotti, G. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 study
    Blumenschein, G., Jr.
    Schwartzberg, L. S.
    Menon, H.
    Mok, T. S. K.
    Stephenson, J. J.
    Beck, J. T.
    Lakshmaiah, K.
    Kracht, K.
    Sikorski, R.
    Kabbinavar, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
  • [25] A multicenter, open-label, phase IIIB trial of erlotinib in patients with advanced non-small cell lung cancer
    Hainsworth, J
    Spigel, D
    O'Neill, V
    Klencke, B
    LUNG CANCER, 2005, 49 : S246 - S247
  • [26] Phase II pharmacodynamic trial of erlotinib in previously treated patients with advanced non-small-cell lung cancer (NSCLC):: Study results
    Felip, Enriqueta
    Rojo, Frederico
    Reck, Martin
    Heller, Astrid
    Klughammer, Barbara
    Maacke, Heiko
    Mocks, Joachim
    Brennscheidt, Ulrich
    Gatzemeier, Ulrich
    Baselga, Jose
    ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [27] Combination therapy with ZD1839 ('Iressa') and docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): preliminary safety results of an open-label, pilot trial
    Manegold, C
    Gatzemeier, U
    Averbuch, S
    Fandi, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S55 - S55
  • [28] Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study
    Heigener, David F.
    Wu, Yi-Long
    van Zandwijk, Nico
    Mali, Pekka
    Horvvood, Keith
    Reck, Martin
    LUNG CANCER, 2011, 74 (02) : 274 - 279
  • [29] Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non-Small-Cell Lung Cancer (NSCLC) An Interim Analysis of 3488 Patients (POLARSTAR)
    Nakagawa, Kazuhiko
    Kudoh, Shoji
    Ohe, Yuichiro
    Johkoh, Takeshi
    Ando, Masahiko
    Yamazaki, Naoya
    Seki, Akihiro
    Takemoto, Shinya
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (08) : 1296 - 1303
  • [30] An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
    de Boer, R.
    Humblet, Y.
    Wolf, J.
    Nogova, L.
    Ruffert, K.
    Milenkova, T.
    Smith, R.
    Godwood, A.
    Vansteenkiste, J.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 486 - 491
12345